Pharmaceutical

Gilead’s Vemlidy expands label to treat paediatric chronic HBV

Vemlidy was first approved to treat adults with HBV in 2016. Its label was expanded in 2022 for use in patients 12 years and older.

Mar 30, 2024 - 00:00
Gilead’s Vemlidy expands label to treat paediatric chronic HBV
Vemlidy was first approved to treat adults with HBV in 2016. Its label was expanded in 2022 for use in patients 12 years and older.
Read the original article

Tags:

Previous Article

A biased edge enhancement method for truss-based community search

Next Article

Arvinas gets grant for treatment of prostate cancer with specific compounds

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Intercept suffers setback with negative AdCom decision for NASH therapy

Intercept suffers setback with negative AdCom decision ...

May 22, 2023

BMS and Prime ink potential $3.5bn deal to develop T cell therapies

BMS and Prime ink potential $3.5bn deal to develop T ce...

Oct 2, 2024

BridgeBio Oncology Therapeutics launches with $200m funding

BridgeBio Oncology Therapeutics launches with $200m fun...

May 5, 2024